Figure 3.

Maximum tumor change from baseline by best overall response based on blinded independent review committee (Japanese ITT population; cutoff date: July 29, 2016). A, dacomitinib arm. B, gefitinib arm. Dashed line at ≥20% increase shows cutoff for progressive disease and at ≥30% reduction shows cutoff for partial response. ITT, intention‐to‐treat. Indeterminate was defined as progression not documented within 12 wk after start of treatment date and where none of the other categories (complete response, partial response, stable disease, or progressive disease) was applicable